Who We Are

Internationally recognized thought leader in perioperative and pain medicine, drug development, and regulatory affairs, Dr. Pergolizzi is highly published in leading journals and frequently serves as a scientific advisor to both public and private companies. A serial entrepreneur who has founded over 20 companies, he trained at the Johns Hopkins School of Medicine and completed his residency at Georgetown University School of Medicine.

Internationally renowned scientist and key opinion leader in pain pathways and analgesics.  Over 30 years industry, academia and  government experience in engineering and pharmacology.  Former team co-leader for analgesics drug discovery at Johnson & Johnson.  Currently affiliated with University of Arizona College of Pharmacy and Temple School of Pharmacy

Senior pharmaceutical executive with 20+ years’ experience, holding a wide range of commercial leadership roles in sales, marketing, and operations.. Proven ability to thrive in entrepreneurial business environments which include successful establishment of multiple biopharmaceutical organizations. Served as key contributor in the selling and acquisition of commercial entities and assets including negotiations to secure ENA001.

20+ years of experience in the development of biophysical and pharmacological interventions targeted primarily at critical care pulmonary function and attenuation of ventilator-induced lung injury. Has established and led clinical development globally for the introduction of disruptive medical technologies, including the creation of a new standard of care and playing a significant scientific role in the path to an IPO.  Prior roles with Vixiar Medical, Vapotherm and Nemours.

Research graduate of Sydney Medical School, University of Sydney, in Sleep. He has served as the VP for Science and Innovation for Vapotherm, Director of Global Research for Oridion, Chief Operating Officer and Head of Technology Research at the Woolcock Institute of Medical Research, Technical Director of the Australian Centre for Chronobiology, Endocrinology and Sleep Sciences, as well as World-wide clinical affairs  and medical education at pulmonary Med-tech companies.

Research professional with a background in early phase clinical studies from both the clinical site and CRO side. Experienced in clinical operations, regulatory compliance, and data management. Earned her MPH at Boston University with a concentration in Epidemiology and Biostatistics and minor in Global Health.

More than 30 years experience with CMC (Chemistry, Manufacturing and Controls), Analytical and Pharmaceutical Development for early development through NDA/BLA submission as well as for marketed products.  Prior roles with Endo Pharmaceuticals, Johnson & Johnson and DuPont.

Seasoned regulatory affairs professional with over two decades of experience spanning pharmaceuticals, biotech, and consulting, including leadership roles at Mallinckrodt Pharmaceuticals and PAREXEL. Since 2017, he has operated Paladin Regulatory Services, providing expert guidance on regulatory strategy and compliance.

Experienced business manager with a strong background across the media, pharmaceutical, and real estate industries. Receiving her Bachelor of Arts in Telecommunications and Addictive Disorders & Recovery from the University of Alabama, she is passionate about using her diverse experience to bring fresh perspectives and value to every project.

Internationally recognized physician, pain specialist, and medical researcher with deep expertise in anesthesiology and pain medicine. He has authored over 300 peer-reviewed publications and is a serial entrepreneur, starting more than 20 companies.

He is, also, the co-founder of NEMA Research, Inc., a specialty CRO, a former subcommittee member of the FDA SUI and SGE VAH Grant Review for Analgesics, and chairman of PAINWEEK and Consultant to National Pain Foundation Board of Directors. Joe is the former director of business development and financial affairs for the Johns Hopkins University School of Medicine Clinical Trials Unit. He also formerly served as a part-time adjunct faculty member in the department of medicine at the Johns Hopkins University School of Medicine.

Dr. Coleman leads National Spine & Pain Centers, the nation’s largest MSO for interventional pain management, overseeing an enterprise of over 1,000 employees. He is a highly sought-after consultant and scientific advisor to the pharmaceutical and medical device industries. His clients have included global leaders such as Abbott, Medtronic, and Collegium, among many others. He also played an early advisory role in the formation of Axsome Therapeutics (NASDAQ: AXSM) and has served on its Board of Directors since 2014.

Raised in Vestal, NY, Dr. Coleman earned his undergraduate degree from Wesleyan University and his medical degree from Johns Hopkins University School of Medicine, where he was honored by the National Institutes of Health for research on the pharmacologic manipulation of nerve transmission. He is a Diplomat of the American Board of Anesthesiology.

Founder and former CEO of Eagle Pharmaceuticals, with prior leadership roles at Par Pharmaceutical and Bristol-Myers Squibb. He serves on the boards of Hackensack Meridian Health and Hackensack University Medical Center and previously served on the Board of Directors of Clinical Data, Inc. and Synthetic Biologics, Inc., both publicly traded pharmaceutical companies.

In 2016, Mr. Tarriff received the prestigious Ernst and Young Entrepreneur Of The Year® Award in the Specialty Pharmaceutical category, New Jersey. The award recognizes outstanding entrepreneurs who demonstrate excellence and extraordinary success in areas such as innovation, financial performance, and personal commitment to their businesses and communities. Mr. Tarriff holds a B.S. in marketing from Pennsylvania State University and an M.B.A. from Rider College.

World renowned expert in areas of anesthesia and pain and advisor to top regulatory agencies. Founder and Head of Anesthesia & Pain Research Unit at Leiden University. Member of several editorial boards and has published 100s of articles in peer reviewed journals. Professor of Anesthesiology at Leiden University Medical Center.

Accomplished international executive with over 20 years experience in the pharma industry. Former Head of Pharmaco-kinetics at Grünenthal GmbH and Vice President TRF Business at Grünenthal USA, Inc. Frequent presenter on abuse prevention of prescription drugs. Former Head Search & Evaluation at Aquestive Therapeutics.

Seasoned healthcare executive with 20+ years of experience, spanning academia, industry and management consulting. Established TrueNorth Lifesciences. Served as a senior principal in the pharma/ medical device consulting practice within IMS Health. MD, Weill Cornell Medical College, MBA Wharton School of Business, M.Sc. Harvard School of Public Health

Internationally renowned scientist and key opinion leader in pain pathways and analgesics.  Over 30 years industry, academia and  government experience in engineering and pharmacology.  Former team co-leader for analgesics drug discovery at Johnson & Johnson.  Currently affiliated with University of Arizona College of Pharmacy and Temple School of Pharmacy

Practicing emergency medicine specialist with experience treating substance abuse and COVID patients at the largest provider of healthcare in NY State, Northwell Health.  Serves as the Medicine Lead for both the Opiate Task Force and Sepsis Task Force.  Research experience at multiple institutions including Northwell Health, Cornell-Presbyterian Hospital, and University of Medicine and Dentistry of New Jersey

Distinguished leader in anesthesiology working to define best-practice. Chairman of the Department of Anesthesiology at Stoney Brook Medicine and former faculty at the Duke Clinical Research Institute.  Founding President of the American Society of Enhanced Recovery (ASER) and dedicated to improving perioperative care through his role in establishing Enhanced Recovery After Surgery (ERAS) programs.